0QKQ.LSE RELIEF THERAPEUTICS Holding AG
- Market cap
- GBP 173M
- P/E
- -
- P/B
- -
- ROE
- -77.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QKQ.LSE undervalued?
Graham numberThe Graham number of RELIEF THERAPEUTICS Holding AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RELIEF THERAPEUTICS Holding AG fundamental analysis
No fundamental analysis for RELIEF THERAPEUTICS Holding AG yet.
RELIEF THERAPEUTICS Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RELIEF THERAPEUTICS Holding AG
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages pres…
Full company profileRELIEF THERAPEUTICS Holding AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RELIEF THERAPEUTICS Holding AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.0K | - | 565K | - | - | 3.32M | 6.08M | 6.03M | 8.42M | 642K | 2.34M |
| Gross Profit | -930K | -3.00K | 147K | -1.00K | - | -8.59M | -12.0M | 4.11M | -2.70M | -1.05M | -1.68M |
| Operating Income | -1.13M | -1.25M | -502K | -947K | -19.3M | -35.2M | -36.5M | -111M | -7.67M | -10.5M | -26.8M |
| EBITDA | -16.5M | -1.79M | -483K | -12.0M | -6.09M | -33.2M | -50.3M | -108M | -16.7M | -8.88M | -23.1M |
| Net Income | -16.8M | -2.89M | -436K | -7.46M | -7.83M | -34.7M | -50.8M | -98.2M | -17.1M | -9.91M | -27.7M |
| EPS | -5.32 | -0.58 | -0.09 | -1.42 | -1.30 | -3.86 | -4.80 | -8.35 | -1.37 | -0.48 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 31.4M | 31.0M | 35.6M | 19.9M | 78.0M | 252M | 189M | 76.4M | 53.2M | 51.5M | 44.1M |
| Total Liabilities | 9.19M | 10.0M | 14.3M | 5.57M | 11.0M | 70.1M | 43.4M | 24.2M | 16.6M | 13.2M | 8.18M |
| Shareholders' Equity | 22.2M | 20.9M | 21.3M | 14.3M | 67.0M | 182M | 145M | 52.2M | 36.7M | 38.3M | 35.9M |
| Cash & Short-term Investments | 394K | 135K | 265K | 129K | 43.2M | 44.8M | 19.2M | 14.6M | 15.1M | 9.47M | 5.32M |
| Total Debt | 878K | 1.01M | 1.05M | 1.74M | 891K | 4.26M | 4.34M | 4.31M | 2.14M | 1.81M | 24.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.89M | -1.17M | -618K | -748K | -18.2M | -35.7M | -24.1M | -17.6M | -2.73M | -6.90M | -34.9M |
| Capital Expenditure | 11.0K | 0.00 | 0.00 | 0.00 | 0.00 | 13.7M | 521K | 446K | 14.0K | 6.24M | 176K |
| Free Cash Flow | -2.90M | -1.17M | -618K | -748K | -18.2M | -49.4M | -24.6M | -18.1M | -2.74M | -13.1M | -35.1M |
| Ratios | |||||||||||
| ROE | -75.7% | -13.8% | -2.0% | -52.2% | -11.7% | -19.1% | -34.9% | -188.0% | -46.7% | -25.8% | -77.1% |
| ROA | -53.6% | -9.3% | -1.2% | -37.6% | -10.0% | -13.8% | -26.9% | -128.5% | -32.2% | -19.2% | -62.8% |
| Net Profit Margin | -112,226.7% | - | -77.2% | - | - | -1,045.0% | -835.2% | -1,627.4% | -203.4% | -1,543.0% | -1,182.3% |
| Debt to Equity | 0.04x | 0.05x | 0.05x | 0.12x | 0.01x | 0.02x | 0.03x | 0.08x | 0.06x | 0.05x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RELIEF THERAPEUTICS Holding AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | GBP 6.81M | 0.64 | - |
| 2021 | GBP 67.7M | 7.54 | - |
| 2020 | GBP 58.2M | 9.65 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:400 on May 5, 2023.
Who owns RELIEF THERAPEUTICS Holding AG
- Insiders 50.33%
- Institutions 18.74%
- Public & others 30.93%
- Shares outstanding 634M
- Free float 51.2M
RELIEF THERAPEUTICS Holding AG company profile
- Company name
- RELIEF THERAPEUTICS Holding AG
- Ticker
- 0QKQ.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 10
- Fiscal year end
- December
- Address
- Avenue de Sécheron 15, Geneva, Switzerland, 1202
- Phone
- 41 21 552 08 01
- Website
- mindmazetherapeutics.com
About RELIEF THERAPEUTICS Holding AG
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
RELIEF THERAPEUTICS Holding AG management
4- Mr. Zachery W. HendersonCEO & Director · born 1973
- Mr. Jeremy Meinen CPAChief Financial Officer · born 1989
- Mr. Alexandre CapetChief Operating & Strategy Officer · born 1973
- Mr. Frédéric CondoloChief Technology Officer · born 1973